Literature DB >> 18294965

New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications.

Anna Rosa Sannella1, Angela Casini, Chiara Gabbiani, Luigi Messori, Anna Rita Bilia, Francesco Franco Vincieri, Giancarlo Majori, Carlo Severini.   

Abstract

The clinically established gold-based antiarthritic drug auranofin (AF) manifests a pronounced reactivity toward thiol and selenol groups of proteins. In particular, AF behaves as a potent inhibitor of mammalian thioredoxin reductases causing severe intracellular oxidative stress. Given the high sensitivity of Plasmodium falciparum to oxidative stress, we thought that auranofin might act as an effective antimalarial agent. Thus, we report here new experimental results showing that auranofin and a few related gold complexes strongly inhibit P. falciparum growth in vitro. The observed antiplasmodial effects probably arise from direct inhibition of P. falciparum thioredoxin reductase. The above findings and the safe toxicity profile of auranofin warrant rapid evaluation of AF for malaria treatment in animal models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294965     DOI: 10.1016/j.febslet.2008.02.028

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  44 in total

1.  On the mechanism and rate of gold incorporation into thiol-dependent flavoreductases.

Authors:  Fulvio Saccoccia; Francesco Angelucci; Giovanna Boumis; Maurizio Brunori; Adriana E Miele; David L Williams; Andrea Bellelli
Journal:  J Inorg Biochem       Date:  2011-11-27       Impact factor: 4.155

2.  X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action.

Authors:  Derek Parsonage; Fang Sheng; Ken Hirata; Anjan Debnath; James H McKerrow; Sharon L Reed; Ruben Abagyan; Leslie B Poole; Larissa M Podust
Journal:  J Struct Biol       Date:  2016-02-12       Impact factor: 2.867

3.  Identification of a thioredoxin reductase from Babesia microti during mammalian infection.

Authors:  Shaoruo Zhao; Haiyan Gong; Yongzhi Zhou; Houshuang Zhang; Jie Cao; Jinlin Zhou
Journal:  Parasitol Res       Date:  2016-05-11       Impact factor: 2.289

Review 4.  The biological activity of auranofin: implications for novel treatment of diseases.

Authors:  J M Madeira; D L Gibson; W F Kean; A Klegeris
Journal:  Inflammopharmacology       Date:  2012-09-11       Impact factor: 4.473

5.  Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.

Authors:  Nathan P Wiederhold; Thomas F Patterson; Anand Srinivasan; Ashok K Chaturvedi; Annette W Fothergill; Floyd L Wormley; Anand K Ramasubramanian; José L Lopez-Ribot
Journal:  Virulence       Date:  2016-06-07       Impact factor: 5.882

6.  Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Authors:  Juan C Engel; Kenny K H Ang; Steven Chen; Michelle R Arkin; James H McKerrow; Patricia S Doyle
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 7.  Polypharmacology: drug discovery for the future.

Authors:  A Srinivas Reddy; Shuxing Zhang
Journal:  Expert Rev Clin Pharmacol       Date:  2013-01       Impact factor: 5.045

8.  Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains.

Authors:  Yozane Hokai; Boruch Jurkowicz; Jacob Fernández-Gallardo; Nuruddinkodja Zakirkhodjaev; Mercedes Sanaú; Theodore R Muth; María Contel
Journal:  J Inorg Biochem       Date:  2014-05-28       Impact factor: 4.155

9.  Beneficial effect of aurothiomalate on murine malaria.

Authors:  Ioana Alesutan; Diwakar Bobbala; Syed M Qadri; Adriana Estremera; Michael Föller; Florian Lang
Journal:  Malar J       Date:  2010-05-07       Impact factor: 2.979

Review 10.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.